Schedule 13D ownership disclosure
EIDOS THERAPEUTICS INC
Security class unavailable · CUSIP: 28249H104
Event date: 2019-07-03
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 66.7300%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-19-190741
- Form type
- SC 13D
- Filer
- BridgeBio Pharma, Inc.
- CIK
- CIK 1743881
- Filed
- Jul 09, 2019
- Reporting period
- Jul 03, 2019
- Description
- Schedule 13D beneficial ownership